Literature DB >> 15317546

Modern management of pancreatic carcinoma.

D Goldstein1, S Carroll, M Apte, G Keogh.   

Abstract

Pancreatic cancer remains a fearsome disease. New insights into the molecular pathogenesis may influence choice of treatment modalities and provide avenues for novel therapeutic strategies for testing in the clinic. The survival rate of patients with all stages of disease is poor and clinical trials are appropriate alternatives for treatment and should be considered. Surgical resection, when possible, remains the primary treatment modality and can result in long-term cure. Less invasive techniques such as laparoscopy may reduce the rate of unnecessary laparotomies. The role of adjuvant therapy is re-emerging. Patients with unresectable and metastatic disease are incurable and optimal palliation is the goal. These patients may benefit from palliative bypass of biliary or duodenal obstruction if symptomatic. Pain associated with local tumour infiltration may be palliated with radiation, with or without chemotherapy, or with coeliac nerve blocks or local neurosurgical procedures. Chemotherapy with gemcitabine has modest objective response rates but has been shown to improve symptoms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15317546     DOI: 10.1111/j.1444-0903.2004.00658.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  13 in total

1.  A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer.

Authors:  Jill P Smith; John F Harms; Gail L Matters; Christopher O McGovern; Francesca M Ruggiero; Jiangang Liao; Kristin K Fino; Emily E Ortega; Evan L Gilius; John A Phillips
Journal:  Cancer Biol Ther       Date:  2012-02-01       Impact factor: 4.742

2.  Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer.

Authors:  Jill P Smith; Sandra I Bingaman; David T Mauger; Harold H Harvey; Laurence M Demers; Ian S Zagon
Journal:  Open Access J Clin Trials       Date:  2010-03-01

3.  Effects of ginsenoside Rh2 on growth and migration of pancreatic cancer cells.

Authors:  Xi-Ping Tang; Guo-Du Tang; Chun-Yun Fang; Zhi-Hai Liang; Lu-Yi Zhang
Journal:  World J Gastroenterol       Date:  2013-03-14       Impact factor: 5.742

4.  Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer.

Authors:  D Ohlund; C Lundin; B Ardnor; M Oman; P Naredi; M Sund
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

5.  Prognostic factors in patients with pancreatic cancer.

Authors:  DE-Xiang Zhang; Yue-DI Dai; Su-Xu Yuan; Li Tao
Journal:  Exp Ther Med       Date:  2011-12-08       Impact factor: 2.447

6.  Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies.

Authors:  Bryan Holcomb; Michele T Yip-Schneider; Jesus M Matos; Jennifer Dixon; Jason Kennard; Julie Mahomed; Rajasubramaniam Shanmugam; Judith Sebolt-Leopold; C Max Schmidt
Journal:  J Gastrointest Surg       Date:  2007-11-30       Impact factor: 3.452

7.  The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer.

Authors:  Thomas E Adrian; Rene Hennig; Helmut Friess; Xianzhong Ding
Journal:  PPAR Res       Date:  2009-01-27       Impact factor: 4.964

8.  Endoscopic Ultrasound-Guided Fine Needle Aspiration Accurately Diagnoses Smaller Pancreatic Neuroendocrine Tumors Compared To Computer Tomography-Guided Fine Needle Aspiration.

Authors:  Jeremy Wang; Jihane N Benhammou; Kevin Ghassemi; Stephen Kim; Alireza Sedarat; James Farrell; Joseph R Pisegna
Journal:  J Gastroenterol Pancreatol Liver Disord       Date:  2017-03-27

9.  Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop.

Authors:  Daniel Öhlund; Oskar Franklin; Erik Lundberg; Christina Lundin; Malin Sund
Journal:  BMC Cancer       Date:  2013-03-26       Impact factor: 4.430

10.  Role of Peroxisome Proliferator-Activated Receptor β/δ and B-Cell Lymphoma-6 in Regulation of Genes Involved in Metastasis and Migration in Pancreatic Cancer Cells.

Authors:  Jeffrey D Coleman; Jerry T Thompson; Russell W Smith; Bogdan Prokopczyk; John P Vanden Heuvel
Journal:  PPAR Res       Date:  2013-05-02       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.